Overexpression of CDKN2B is involved in poor gastric cancer prognosis

Abstract

The objective of this investigation is to elucidate the clinical significance of cyclin-dependent kinase inhibitor 2B (CDKN2B) expression regarding gastric cancer (GC), as well as to detect the involvement of CDKN2B expression in the clinicopathological indexes and prognosis of GC. Immunohistochemical analysis was used for identification of CDKN2B expression in GC specimens. Chi-square (χ 2 ) test was applied to detect the association of CDKN2B expression and clinicopathological parameters of GC. The involvement of CDKN2B expression in the prognosis was analyzed via univariate and multivariate analysis. It was indicated that relative to the corresponding para-carcinoma tissues, CDKN2B expression was notably upregulated in GC specimens. Moreover, the expression of CDKN2B was strongly correlated with the differentiation (r = −0.182; P = .015), invasion (r = −0.157; P = .038), distant metastases (r = −0.196; P = .004), and TNM stage (r = −0.204; P = .005).Nevertheless, no remarkable variance was related to age, tumor loci, or sex.Kaplan-Meier survival curve and univariate analysis showed that CDKN2B overexpression predicted poorer disease-free survival (P = .007) and overall survival (P = .005) in those with GC. In addition, Cox proportional hazards regression model revealed that CDKN2B was an isolated biomarker of diseasefree survival and overall survival in patients with GC. Taken together, our data demonstrated that the overexpression of CDKN2B could be an isolated factor for GC prognostic in patients. CDKN2B gene may be a useful target and new treatment for improving the prognosis of GC.

Identification of kinesin family member 3B (KIF3B) as a molecular target for gastric cancer

“…Therapeutic targets for GC have been developed and some targeted therapeutic drugs have been tested in clinical trials . However, the prognosis and mortality of patients with advanced GC are still poor . Therefore, it is still badly needed to find novel molecular targets to control the progression and development of GC.…”

KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients

“…As tumor suppressor genes, RB1 or TP53 mutation/copy loss was also identified in other studies in GIST, 26 and the inactivating mutations of RB1 and TP53 correlate with metastasis/recurrence in GIST. CDKN2B has been reported to be correlated with the poor prognosis of gastric cancer, 40 liver cancer, 41 oral cancer, 42 ovarian cancer, 43 and so on. LRP1B deletion is associated with poor outcome for glioblastoma patients 44 and acquired chemotherapy resistance in ovarian cancer patients 45 .…”

Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer

“… 35 Mutant and aberrant expression of CDKN genes is frequently encountered in cancer and is associated with patient survival. 36 - 39 Copy number loss and large deletion of the CDKN2A/B also lead to poor prognosis. 33 , 34 Consistently, our study showed that mutations of CDKN1C/2A/2C and CNV of CDKN2A/B were associated with poor prognosis in gastric cancer.…”